Tumor growth was delayed in mammary carcinoma mouse models,100 although in phase I (NCT02452424) and a phase II trial (NCT03336216), PXL3397 plus anti-PD-L1 therapy failed to exhibit satisfying therapeutic effects.101 Administration of the dual inhibitor BMS-687681, targeting both CCR2 and CCR5, led to a superior survival rate when combined with RT+αPD-1 therapy in a PDAC mouse model.102. Here, CCR5 is linked to neoplasm.